Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study

BACKGROUND: Tixagevimab and cilgavimab (Evusheld) are 2 fully human monoclonal antibodies that received emergency-use authorization on December 21, 2021, for pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in patients who are moderate–severely immunocompromised. The real-world effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Aakash, Hashash, Jana G, Kochhar, Gursimran S, Farraye, Francis A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Fellows' Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482141/
https://www.ncbi.nlm.nih.gov/pubmed/37680248
http://dx.doi.org/10.1093/crocol/otad047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482141/
https://www.ncbi.nlm.nih.gov/pubmed/37680248
http://dx.doi.org/10.1093/crocol/otad047

Ejemplares similares